Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,856 total articles
Amylyx (AMLX) is reshaping its story around avexitide, a once-daily GLP-1 receptor antagonist for post-bariatric hypoglycemia, supported by recent pipeline momentum and improving technicals. The company trades at a market cap of roughly $2.8B with negative EPS but a clear commercial runway. This trade idea lays out a long trade with entry, targets,…
Candel Therapeutics ($CADL) is a clinical-stage immunotherapy company that has moved several programs into late-stage development and is funding launch readiness for localized prostate cancer. The stock is trading around $10.60 with a market cap near $816M. Positive phase 3 signals, a recent public offering to support commercialization, and still-h…
Amgen is trading like a steady cash machine while quietly layering optionality from a weight-loss franchise and late-stage pipeline programs. At $406.92 the market underestimates upside from product launches, durable free cash flow of $10.175B, and a healthy dividend. This trade targets $470 with a clear stop at $369 over a 180 trading-day horizon.
Kinetik (KNTK) owns a dense set of Permian gathering, processing and NGL/crude pipelines that should benefit from persistent takeaway bottlenecks. The stock trades near $50 with a ~6.5% cash yield and an EV/EBITDA of 13.9. We propose a mid-term long trade to capture catalyst-driven re-rating and near-term distribution income, while protecting capit…
Palantir's Q2 results were outstanding - $1.9B revenue and a guidance raise - but the Q that changed the game was the market's willingness to re-rate the stock. This trade idea targets a pullback entry for a mid-term swing to capture further multiple expansion while keeping a tight stop to limit valuation risk.
Constellation Energy (CEG) is a cash-generating nuclear operator sitting squarely in the path of surging electricity demand from AI data centers and renewed government backing for nuclear expansion. The stock trades around $265 with a market cap near $95B, free cash flow of roughly $1.14B and a P/E in the mid-20s. For traders who want an event-driv…
Permian Resources (PR) is a mid-cap Permian Basin operator with a solid cash profile, low leverage and improving unit economics. At roughly $20/share the stock offers modest upside to consensus targets while providing income via a ~2.8% yield. This trade idea lays out a clear entry ($19.95), stop ($18.00) and target ($24.00) for a mid-term swing (4…
TPG RE Finance Trust's capital structure and current valuation leave room for preferred income plays. For retail traders who can't access the Series C preferred directly, buying the common at current levels offers a way to capture recovery-linked upside while collecting a meaningful distribution. We lay out entry, stop and target with catalysts and…
Palantir's Q2 beat and raised guidance have turned the enterprise AI adoption story from promise to near-term earnings reality. With revenue growth re-accelerating, improving cash generation, and technical momentum, we lay out a mid-term trade plan to capture further upside while defining risk with a disciplined stop.
Align Technology (ALGN) offers a compelling asymmetric trade: improving fundamentals and structural market growth paired with a valuation that looks conservative versus the company’s cashflow and growth runway. Buy at current levels with a $200 target and $150 stop; horizon 180 trading days.
Microsoft's post-earnings surge looks more than a short-lived bounce. Strong AI monetization, 27%-plus cloud growth, and a fortress balance sheet justify a tactical long. This idea outlines an entry at $505.00, a stop at $485.00, and a $560.00 target over a mid-term horizon (45 trading days).
Arm's licensing model and accelerating server CPU momentum make the recent pullback an attractive swing entry. The stock trades near $284 after a $1.29B fiscal Q1 beat and an updated data-center revenue narrative. This idea outlines a clear entry at $275.00, a stop at $250.00 and a target of $340.00 over a mid-term (45 trading days) horizon, with d…
FedEx's shift toward higher-margin customers and the payoff from an extensive network transformation support a buy here. At $315.87 the shares trade at ~16.9x reported EPS with EV/EBITDA of 8.7x and free cash flow of $5.12B — valuations that allow upside while providing a margin of safety against cyclical risk.
Vermilion Energy ($VET) offers a risk-adjusted long entry ahead of balance-sheet repair and positioning changes. Market-cap of $1.675B, a modest PB of 1.16 and a 3.3% yield pair with rising short interest and bullish technicals — a setup worth a tactical buy for the next 45 trading days.
First Phosphate (FRSPF) is an OTC microcap that has seen a meaningful drop in short interest over the past months while technicals are turning bullish. Coupled with visible short-volume spikes and above-average liquidity for an OTC name, the setup favors a tactical long: a momentum-driven short-covering run could lift the stock through key moving a…
Sprouts Farmers Market is showing early signs of a sales rebound while retaining high gross margins and strong free cash flow. At roughly $8.1B market cap with EV/EBITDA near 9.5 and a P/E in the high teens, the stock looks reasonably valued for a retailer that still has growth runway from new-store openings and product wins. This trade idea is a t…
GrafTech makes graphite electrodes and needle coke used in electric arc furnace steelmaking and other industrial processes. With commodity-driven cyclicality priced in, the stock's sub-$8 valuation reflects stress rather than a recovery scenario. We lay out a mid-term (45 trading days) entry at $7.64, stop at $6.00 and a $12.00 target tied to an el…
Alphatec (ATEC) cratered after a May earnings report that flagged installation timing issues and missed EOS unit deliveries. The stock has stabilized and is showing bullish technicals while trading at a cheaper revenue multiple than the 2025 peak. This is a tactical long: enter on a gentle dip, use a tight stop to respect execution risk, and target…
Corebridge Financial is a defensive insurance franchise with a surprisingly attractive capital-return runway. Recent reinsurance transactions, a steady dividend, and management's push toward shareholder distributions are underappreciated by the market. The trade: enter at $34.00, stop $30.00, target $40.00—position trade, horizon ~45–180 trading da…
Paymentus is a cloud-first payments platform with accelerating transaction volume and a strong cash flow profile. At $40.09 the stock trades at a premium but the company’s debt-free balance sheet, positive free cash flow of $159M and recent double-digit to high-double-digit revenue growth create an attractive setup if management deploys capital int…
Centene's recent membership declines look ugly at first glance, but management's shift to prioritize margins, a surprisingly cheap valuation (EV/EBITDA ~5.2, P/FCF ~3.5), and regulatory tailwinds in Medicare create a practical trade: buy on weakness with a tight stop. This is a mid-term swing idea that bets on margin recovery, rate clarity, and imp…
Amazon is showing signs of stronger AWS momentum while the company is entering a heavier investment cycle that will pressure free cash flow near term. The setup favors a mid-term long trade that captures upside from multiple expansion and continued AWS growth, but it requires disciplined risk management against capex- and consumer-retail headwinds.
Nano Labs (NA) trades like a microcap walking back from panic. With a market cap of just $44.3M, a price-to-book under 0.4 and a P/E near 2.0, the stock is priced for disappointment. Recent technical stabilization, CEO insider buying, and a clear pipeline of AI and data-center initiatives suggest the downside is limited and upside is meaningful ove…
Revolution Medicines (RVMD) is a speculative, clinical-stage oncology name that has re-rated sharply in 2026 after Breakthrough Therapy recognition for daraxonrasib and fresh institutional buying. The setup combines a binary regulatory/catalyst path with elevated short interest and a valuation that still reflects pre-revenue status. This trade idea…
Disney just reported a clean Q3 with 7% revenue growth and a significant boost to profitability. With management pushing a $9 billion buyback, free cash flow of roughly $8.3 billion, and forward earnings that analysts peg in the low-teens multiple, the risk/reward supports a measured long into the next content and parks cycle. This idea lays out en…
